{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:01:47Z","timestamp":1790215307747,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.smim.2011.08.014","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T20:46:29Z","timestamp":1323463589000},"page":"143-147","source":"Crossref","is-referenced-by-count":18,"title":["The state of therapy for removal of alloantibody producing plasma cells in transplantation"],"prefix":"10.1016","volume":"24","author":[{"given":"Matthew J.","family":"Everly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul I.","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2011.08.014_bib0005","first-page":"291","article-title":"Retrospective antibody analysis of thirty patients with kidney graft failure","author":"Kinukawa","year":"2006","journal-title":"Clinical Transplants"},{"issue":"8","key":"10.1016\/j.smim.2011.08.014_bib0010","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies","volume":"74","author":"Lee","year":"2002","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.smim.2011.08.014_bib0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.humimm.2006.02.007","article-title":"Frequency of MIC antibody in rejected renal transplant patients without HLA antibody","volume":"67","author":"Mizutani","year":"2006","journal-title":"Human Immunology"},{"issue":"7","key":"10.1016\/j.smim.2011.08.014_bib0020","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.TP.0000055833.65192.3B","article-title":"Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome","volume":"75","author":"Worthington","year":"2003","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.smim.2011.08.014_bib0025","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/TP.0b013e3181a44206","article-title":"Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts","volume":"87","author":"Lachmann","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.smim.2011.08.014_bib0030","first-page":"171","article-title":"Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up","author":"Lachmann","year":"2006","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0035","first-page":"255","article-title":"Detection of HLA and MICA antibodies before kidney graft failure","author":"Mizutani","year":"2006","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0040","first-page":"265","article-title":"Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience","author":"Ozawa","year":"2006","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0045","first-page":"255","author":"Ozawa","year":"2007","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0050","first-page":"305","article-title":"Longitudinal testing of seventy-six renal allograft patients for HLA antibodies: Maastricht experience","author":"van den Berg-Loonen","year":"2006","journal-title":"Clinical Transplants"},{"issue":"4","key":"10.1016\/j.smim.2011.08.014_bib0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.humimm.2005.01.021","article-title":"Humoral theory of transplantation: mechanism, prevention, and treatment","volume":"66","author":"Cai","year":"2005","journal-title":"Human Immunology"},{"issue":"8","key":"10.1016\/j.smim.2011.08.014_bib0060","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.humimm.2009.04.019","article-title":"Monitoring and treating posttransplant human leukocyte antigen antibodies","volume":"70","author":"Everly","year":"2009","journal-title":"Human Immunology"},{"issue":"6","key":"10.1016\/j.smim.2011.08.014_bib0065","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1034\/j.1600-6143.2003.00135.x","article-title":"Humoral theory of transplantation","volume":"3","author":"Terasaki","year":"2003","journal-title":"American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"issue":"5","key":"10.1016\/j.smim.2011.08.014_bib0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.coi.2005.07.018","article-title":"Humoral theory of transplantation: further evidence","volume":"17","author":"Terasaki","year":"2005","journal-title":"Current Opinion in Immunology"},{"issue":"3","key":"10.1016\/j.smim.2011.08.014_bib0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/TP.0b013e31817c4cb8","article-title":"Human leukocyte antigen antibodies and chronic rejection: from association to causation","volume":"86","author":"Terasaki","year":"2008","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.smim.2011.08.014_bib0080","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.healun.2010.05.006","article-title":"Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation","volume":"29","author":"Hachem","year":"2010","journal-title":"The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation"},{"issue":"3","key":"10.1016\/j.smim.2011.08.014_bib0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2215\/CJN.01651105","article-title":"Presensitization: the problem and its management","volume":"1","author":"Jordan","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1016\/j.smim.2011.08.014_bib0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.surg.2004.08.002","article-title":"Conquering absolute contraindications to transplantation: positive-crossmatch and ABO-incompatible kidney transplantation","volume":"137","author":"Dean","year":"2005","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.smim.2011.08.014_bib0095","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1016\/j.smim.2011.08.014_bib0100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00007890-200009270-00006","article-title":"Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients","volume":"70","author":"Montgomery","year":"2000","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.smim.2011.08.014_bib0105","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2007.01895.x","article-title":"Transplant glomerulopathy: subclinical incidence and association with alloantibody","volume":"7","author":"Gloor","year":"2007","journal-title":"American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"issue":"12","key":"10.1016\/j.smim.2011.08.014_bib0110","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"issue":"5","key":"10.1016\/j.smim.2011.08.014_bib0115","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-6143.2009.02577.x","article-title":"Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss","volume":"9","author":"Everly","year":"2009","journal-title":"American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"issue":"8","key":"10.1016\/j.smim.2011.08.014_bib0120","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/TP.0b013e3181cbac02","article-title":"Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection","volume":"89","author":"Everly","year":"2010","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.smim.2011.08.014_bib0125","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination Plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"issue":"12","key":"10.1016\/j.smim.2011.08.014_bib0130","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.smim.2011.08.014_bib0135","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/ki.2008.249","article-title":"Characterization of intra-graft B cells during renal allograft rejection","volume":"74","author":"Zarkhin","year":"2008","journal-title":"Kidney International"},{"issue":"10","key":"10.1016\/j.smim.2011.08.014_bib0140","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"10.1016\/j.smim.2011.08.014_bib0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production","volume":"9","author":"Perry","year":"2009","journal-title":"American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"issue":"4","key":"10.1016\/j.smim.2011.08.014_bib0150","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1084\/jem.20042060","article-title":"Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization","volume":"201","author":"Blink","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"issue":"4","key":"10.1016\/j.smim.2011.08.014_bib0155","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood-2004-07-2507","article-title":"Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response","volume":"105","author":"Odendahl","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.smim.2011.08.014_bib0160","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.smim.2011.08.014_bib0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.it.2003.11.004","article-title":"B cells? Plasma-cell differentiation and the unfolded protein response","volume":"25","author":"Gass","year":"2004","journal-title":"Trends in Immunology"},{"issue":"1","key":"10.1016\/j.smim.2011.08.014_bib0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10495-005-3088-0","article-title":"Role of the unfolded protein response in cell death","volume":"11","author":"Kim","year":"2006","journal-title":"Apoptosis"},{"issue":"12","key":"10.1016\/j.smim.2011.08.014_bib0175","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/TP.0b013e3181ff87b1","article-title":"Protective immunity remains intact after antibody removal by means of proteasome inhibition","volume":"90","author":"Everly","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.smim.2011.08.014_bib0180","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00007890-200107270-00005","article-title":"A proteasome inhibitor effectively prevents mouse heart allograft rejection","volume":"72","author":"Luo","year":"2001","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.smim.2011.08.014_bib0185","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/01.TP.0000128855.10397.DB","article-title":"Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection","volume":"78","author":"Wu","year":"2004","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.smim.2011.08.014_bib0190","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1034\/j.1600-6143.2002.21006.x","article-title":"On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants","volume":"2","author":"Wu","year":"2002","journal-title":"American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"issue":"1","key":"10.1016\/j.smim.2011.08.014_bib0195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.transproceed.2008.10.073","article-title":"Proteasome inhibition reduces donor-specific antibody levels","volume":"41","author":"Everly","year":"2009","journal-title":"Transplantation Proceedings"},{"issue":"10","key":"10.1016\/j.smim.2011.08.014_bib0200","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"issue":"Suppl. 4","key":"10.1016\/j.smim.2011.08.014_bib0205","first-page":"467","article-title":"DSA monitoring may improve donor specific HLA-antibody relapse and refratoriness following proteasome inhibition","volume":"10","author":"Everly","year":"2010","journal-title":"American Journal of Transplantion"},{"issue":"1","key":"10.1016\/j.smim.2011.08.014_bib0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/TP.0b013e3181c280f9","article-title":"Acute humoral rejection in a lung recipient: reversion with bortezomib","volume":"89","author":"Neumann","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.smim.2011.08.014_bib0215","first-page":"421","article-title":"Bortezomib in lung transplantation: a promising start","author":"Neumann","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0220","first-page":"385","article-title":"Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection","author":"Al Meshari","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0225","first-page":"491","article-title":"Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization","author":"Boothpur","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0230","first-page":"455","article-title":"Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases","author":"Cooper","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0235","first-page":"485","article-title":"Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation","author":"Djamali","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0240","first-page":"475","article-title":"Bortezomib for refractory antibody-mediated cardiac allograft rejection","author":"Eckman","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0245","first-page":"443","article-title":"Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients","author":"Govil","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0250","first-page":"407","article-title":"Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients\u2014case report","author":"Hamawi","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0255","first-page":"479","article-title":"Bortezomib for acute humoral rejection in two repeat transplant recipients","author":"Hardinger","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0260","first-page":"499","article-title":"Use of bortezomib for prevention and treatment of rejection in sensitized patients","author":"Hartono","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0265","first-page":"387","article-title":"Bortezomib affects the function of human B cells: possible implications for desensitization protocols","author":"Heidt","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0270","first-page":"465","article-title":"Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation","author":"Island","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0275","first-page":"439","article-title":"Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant","author":"Kumar","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0280","first-page":"351","article-title":"Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series","author":"Lachmann","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0285","first-page":"425","article-title":"Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?","author":"Lee","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0290","first-page":"369","article-title":"Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran in Mexico City","author":"Leyva","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0295","first-page":"361","article-title":"Bortezomib in the treatment of antibody-mediated rejection\u2014a report of 3 cases","author":"Mai","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0300","first-page":"347","article-title":"Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation\u2014a case report","author":"Patel","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0305","first-page":"343","article-title":"Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC","author":"Pavlakis","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0310","first-page":"339","article-title":"Bortezomib in kidney transplant desensitization: a case report","author":"Raghavan","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0315","first-page":"433","article-title":"Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports","author":"Sberro-Soussan","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0320","first-page":"431","article-title":"Bortezomib rescue in refractory acute humoral rejection\u2014report of a case","author":"Shapiro","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0325","first-page":"471","article-title":"Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy","author":"Stuckey","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0330","first-page":"415","article-title":"Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment","author":"Wahrmann","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0335","first-page":"393","article-title":"Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants","author":"Weston","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0340","first-page":"401","article-title":"Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports","author":"Wong","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0345","first-page":"359","article-title":"Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol","author":"Zhu","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0350","first-page":"323","article-title":"A summary of bortezomib use in transplantation across 29 centers","author":"Everly","year":"2009","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0355","first-page":"363","article-title":"Bortezomib for desensitization of patients on a waiting list for deseased donor kideny transplant: experience in Mexico City","author":"Marino-Vazquez","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0360","first-page":"369","article-title":"Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran in Mexico City: an update","author":"Leyva","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0365","first-page":"383","article-title":"Bortezomib as adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum","author":"Al Meshari","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0370","first-page":"391","article-title":"Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report","author":"Schwaiger","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0375","first-page":"397","article-title":"Targeting alloantibody production with bortezomib: does it make more sense?","author":"Lee","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0380","first-page":"405","article-title":"1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection","author":"Shapiro","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0385","first-page":"409","article-title":"Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment","author":"Sberro-Soussan","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0390","first-page":"415","article-title":"Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases","author":"Cooper","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0395","first-page":"421","article-title":"Rescue therapy for acute antibody mediated rejection with proteasome inhibitor after kidney transplantation","author":"Manitpisitkul","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0400","first-page":"429","article-title":"Bortezomib as a rescue therapy for antibody mediated rejection: a single-center experience","author":"Hardinger","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0405","first-page":"437","article-title":"Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection","author":"Lubetzky","year":"2010","journal-title":"Clinical Transplants"},{"key":"10.1016\/j.smim.2011.08.014_bib0410","first-page":"353","article-title":"An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers","author":"Everly","year":"2010","journal-title":"Clinical Transplants"},{"issue":"S2","key":"10.1016\/j.smim.2011.08.014_bib0415","first-page":"192","article-title":"Intermediate-term global toxicity analysis of proteasome inhibitor-based antihumoral therapy","volume":"11","author":"Schmidt","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"Suppl. 4","key":"10.1016\/j.smim.2011.08.014_bib0420","first-page":"44","article-title":"Depletion of alloantibody-secreting plasma cells by proteasome inhibition improves desensitization","volume":"10","author":"Raghavaiah","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl. 4","key":"10.1016\/j.smim.2011.08.014_bib0425","first-page":"44","article-title":"A prospective, staged trial of proteasome inhibitor-based therapy for reduction of HLA sensitization in kidney transplant candidates","volume":"10","author":"Walsh","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1016\/j.smim.2011.08.014_bib0430","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.smim.2011.08.014_bib0435","first-page":"433","article-title":"Results of PX 171 003 A1, an open label, single arm phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"116","author":"Siegel","year":"2010","journal-title":"Blood"},{"issue":"9767","key":"10.1016\/j.smim.2011.08.014_bib0440","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104453231100090X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104453231100090X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T01:28:29Z","timestamp":1543368509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104453231100090X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S104453231100090X"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2011.08.014","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}